- Octane Medical Group CEO Timothy Smith. KINGSTON, Ontario and MELSUNGEN, Germany, June 07, 2024 (GLOBE NEWSWIRE) -- Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun.
The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine. The orthobiologics platform currently includes two products: NOVOCART 3D, which implants a collagen-based matrix scaffold seeded with cartilage cells into the defective area, and NOVOCART Inject, an injectable mixture of cartilage cells and PEG-albumin-hyaluronic acid hydrogel.
“Octane previously partnered with B. Braun for more than 10 years to scale up production of living-tissue orthopedic implants," said Timothy Smith, CEO and co-founder of Octane, a global leader in regenerative medicine with the most advanced technologies in cell therapy, spinal implants, medical imaging and bioelectricity. "This acquisition brings the NOVOCART autologous chondrocyte implantation (ACI) technology for articular cartilage repair into the innovation portfolio at Octane, giving the company full ownership of the NOVOCART value chain – from design development, clinical trials and manufacturing through to sales, distribution and clinical use.
" Pivotally, the acquisition also allows Octane to leverage the automa.